Biotech Values

[mcbio]

I don't disagree. The schizophrenia trial that reports in early 2013 is possibly the next catalyst and by that time TRGT will probably have less cash than the current marketcap.

And hasn't the schizophrenia drug already disappointed before, either in this indication or perhaps in a different indication? I honestly don't know what they have left in the pipeline that instills any confidence. I'm all for bottom-fishing and buying out-of-favor biotechs but there has to be something in the pipeline that I think can generate interest down the road (can't just be cheap valuation). I just don't see it here. I could of course be wrong. Wouldn't be the first time. ; )